Tizanidine

Generic Name: Tizanidine

Brand Names: Zanaflex

Drug Type: Small Molecule

Chemical Formula: C_₉H_₈ClN_₅S

CAS Number: 51322-75-9

Unique Ingredient Identifier: 6AI06C00GW

Background: Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.

Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm .

Indication: Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities. The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action .

Associated Conditions: Acute Low Back Pain, Drug Withdrawal Headache, Insomnia, Migraine, Pain, Seizures, Spasticity, Muscle

Associated Therapies: Withdrawal From Addictive Substance; Detoxification

Clinical Trials

Effect of Neural Constraints on Movement in Stroke

Early Phase 1

Recruiting

Conditions: Stroke

Interventions: Drug: Placebo
Drug: Tizanidine

First Posted Date: 2024-10-30

Last Posted Date: 2025-05-14

Lead Sponsor: Northwestern University

Target Recruit Count: 64

Registration Number: NCT06666673

Locations: 🇺🇸
Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100, Chicago, Illinois, United States

Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition

Phase 4

Recruiting

Conditions: Cognitive Impairment

Interventions: Drug: metaxalone m640
Drug: tizanidine

First Posted Date: 2024-04-24

Last Posted Date: 2024-06-07

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT06382662

Locations: 🇺🇸
Sun Valley Arthritis Center, Peoria, Arizona, United States

Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial

Phase 4

Not yet recruiting

Conditions: Depressive Disorder, Major

Interventions: Drug: Tizanidine Hcl 4Mg Tab
Drug: Zolpidem Tartrate 10 mg

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Sultan Qaboos University

Target Recruit Count: 90

Registration Number: NCT06303076

Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension

Phase 3

Recruiting

Conditions: Postoperative Urinary Retention
Sacrospinous Vaginal Vault Suspension
Reconstructive Pelvic Surgery

Interventions: Drug: Tizanidine

First Posted Date: 2024-02-14

Last Posted Date: 2025-02-25

Lead Sponsor: Endeavor Health

Target Recruit Count: 30

Registration Number: NCT06258785

Locations: 🇺🇸
NorthShore University Health System, Skokie, Illinois, United States

CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial

Phase 3

Not yet recruiting

Conditions: Back Pain
Neck Pain
Chronic Pain
Opioid Misuse

Interventions: Drug: Tizanidine
Behavioral: Enhanced Usual Care
Drug: Placebo
Behavioral: MI-Opioid Taper

First Posted Date: 2023-09-07

Last Posted Date: 2024-08-16

Lead Sponsor: Stanford University

Target Recruit Count: 375

Registration Number: NCT06027099

Opioid-Free Pain Protocol After Shoulder Arthroplasty

Phase 4

Active, not recruiting

Conditions: Shoulder Arthropathy
Shoulder Pain

Interventions: Drug: Celecoxib
Drug: Pregabalin
Drug: Tramadol
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Ropivicaine
Drug: Epinephrine
Drug: Ketorolac
Drug: Tizanidine
Drug: Magnesium
Drug: Ibuprofen
Drug: Oxycodone Hydrochloride 5 Mg

First Posted Date: 2022-08-05

Last Posted Date: 2025-02-17

Lead Sponsor: Henry Ford Health System

Target Recruit Count: 80

Registration Number: NCT05488847

Locations: 🇺🇸
Henry Ford Health, Detroit, Michigan, United States

TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）

Phase 3

Recruiting

Conditions: Migraine Without Aura
Migraine With Aura

Interventions: Drug: Tizanidine Hydrochloride
Drug: Tizanidine Hydrochloride Placebo

First Posted Date: 2022-08-02

Last Posted Date: 2024-08-01

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 189

Registration Number: NCT05484349

Locations: 🇨🇳
The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

and more 3 locations